200 related articles for article (PubMed ID: 20393638)
1. Saxagliptin in type 2 diabetes.
Billiones R
Drugs Today (Barc); 2010 Feb; 46(2):101-8. PubMed ID: 20393638
[TBL] [Abstract][Full Text] [Related]
2. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
[TBL] [Abstract][Full Text] [Related]
3. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Tahrani AA; Piya MK; Barnett AH
Adv Ther; 2009 Mar; 26(3):249-62. PubMed ID: 19330494
[TBL] [Abstract][Full Text] [Related]
4. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
Schwartz SL
Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
[TBL] [Abstract][Full Text] [Related]
5. Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
Prescrire Int; 2011 Feb; 20(113):33-7. PubMed ID: 21488586
[TBL] [Abstract][Full Text] [Related]
6. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
Lam S; Saad M
Cardiol Rev; 2010; 18(4):213-7. PubMed ID: 20539105
[TBL] [Abstract][Full Text] [Related]
7. Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
Shubrook JH; Colucci RA; Schwartz FL
Expert Opin Pharmacother; 2009 Dec; 10(17):2927-34. PubMed ID: 19929711
[TBL] [Abstract][Full Text] [Related]
8. DPP-4 inhibitors in clinical practice.
Palalau AI; Tahrani AA; Piya MK; Barnett AH
Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
[TBL] [Abstract][Full Text] [Related]
9. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.
Kania DS; Gonzalvo JD; Weber ZA
Clin Ther; 2011 Aug; 33(8):1005-22. PubMed ID: 21802144
[TBL] [Abstract][Full Text] [Related]
10. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
Jain R
Adv Ther; 2015 Nov; 32(11):1065-84. PubMed ID: 26578430
[TBL] [Abstract][Full Text] [Related]
11. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Cook W; Bryzinski B; Slater J; Frederich R; Allen E
Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
[TBL] [Abstract][Full Text] [Related]
12. Saxagliptin and tuberculosis.
Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
[No Abstract] [Full Text] [Related]
13. Saxagliptin + metformin. Mostly disadvantages.
Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
[No Abstract] [Full Text] [Related]
14. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
Jialal I; Dhindsa S
Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
[No Abstract] [Full Text] [Related]
15. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.
LaSalle JR
Postgrad Med; 2010 Jan; 122(1):144-52. PubMed ID: 20107298
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin (Onglyza) for type 2 diabetes.
Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
[No Abstract] [Full Text] [Related]
18. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Yang LP
Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000
[TBL] [Abstract][Full Text] [Related]
19. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Borja-Hart NL; Whalen KL
Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
